Aktuellt
SENASTE
Today, Idogen reported receiving approval from the Swedish Medical Products Agency for its phase l/ll-a trial with IDO 8 in hemophilia patients. The study will be conducted at several European trial centers and has to date submitted applications to Sweden and Norway; patient recruitment is scheduled to commence in Q2. We feel encouraged by today’s news; the results from the phase l/lla-trial constitute a potential value inflection point for the share. The share traded up some 5% on today's news and is currently trading just above Redeye’s Bear case.
LÄS MER
